Medicine and Dentistry
Melanoma
100%
Neoplasm
47%
Immunotherapy
33%
Malignant Neoplasm
31%
Metastatic Melanoma
30%
T Cell
24%
Diseases
23%
Immunity
22%
Overall Survival
15%
Brain Metastasis
14%
Metastatic Carcinoma
14%
Immune Checkpoint Inhibitor
14%
Targeted Therapy
13%
Clinical Trial
12%
Cancer
12%
Cytotoxic T-Cell
11%
Interleukin 2
9%
Ipilimumab
9%
Nivolumab
9%
In Vitro
8%
Uvea Melanoma
8%
Biological Marker
8%
Progression Free Survival
8%
Melanoma Cell
7%
Tumor Cell
7%
Melanoma Skin Cancer
7%
Lymphocyte
7%
Cancer Cell
7%
Immune Checkpoint Blockade
6%
Tumor Infiltrating Lymphocyte
6%
Systemic Therapy
6%
Cell Therapy
6%
Adverse Event
6%
CTLA-4
6%
Connective Tissue Cancer
6%
Oncology
5%
Tumor Microenvironment
5%
extracellular signal regulated kinase
5%
Immune Response
5%
Solid Malignant Neoplasm
5%
MEK Inhibitor
5%
Recurrent Disease
5%
Pembrolizumab
5%
Immune-Related Adverse Events
5%
Drug Megadose
5%
Cancer Immunotherapy
5%
Keyphrases
Melanoma
53%
Metastatic Melanoma
34%
Tumor
23%
T Cells
15%
Interleukin-2
13%
Melanoma Patients
12%
Overall Survival
12%
Immune Checkpoint Inhibitors
11%
Advanced Melanoma
11%
Ipilimumab
10%
Brain Metastases
9%
Programmed Death-ligand 1 (PD-L1)
9%
Melanoma Cells
8%
Nivolumab
8%
Targeted Therapy
8%
CD8+ T Cells
8%
Melanoma Brain Metastases
8%
In Cancer
7%
BRAF Inhibitor (BRAFi)
7%
Clinical Trials
7%
Antitumor Activity
7%
Tumor-infiltrating Lymphocytes
7%
Immune Response
6%
Uveal Melanoma
6%
Phase II Study
6%
Pembrolizumab
6%
Tumor Cells
6%
Solid Tumors
6%
Cancer Immunotherapy
5%
MEK Inhibitor (MEKi)
5%
Progression-free Survival
5%
Natural Killer Cells
5%
Tumor Microenvironment
5%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
5%
Partial Response
5%
Metastasis
5%
Adoptive Cell Therapy
5%
Immunology and Microbiology
T Cell
43%
Immunity
36%
Immunotherapy
28%
Interleukin 2
18%
Cytotoxic T-Cell
17%
Tumor Cell
13%
Immune Response
12%
Peptides
11%
Natural Killer Cell
10%
Cytokine
9%
Lymphocyte
9%
Tumor-Infiltrating Lymphocytes
9%
Melanoma Cell
8%
Cancer Immunotherapy
8%
Regulatory T Cell
7%
CD8
7%
Cancer Cell
7%
Dendritic Cell
7%
Cytotoxic T Cell
7%
Overall Survival
7%
Tumor Antigen
7%
Programmed Cell Death
6%
Immunocompetent Cell
6%
Cytotoxicity
6%
Antineoplastic Activity
6%
B Cell
5%
Antigen Specificity
5%
Lymphokine Activated Killer Cell
5%
Interferon
5%
Lymphokine
5%